HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Massive intravenous immunoglobulin treatment in women with four or more recurrent spontaneous abortions of unexplained etiology: down-regulation of NK cell activity and subsets.

AbstractPROBLEM:
The aims of this study were to investigate the efficacy of massive intravenous immunoglobulin (MIVIg) treatment for women with recurrent spontaneous abortion (RSA) of unexplained etiology, and to investigate changes in peripheral natural killer (NK) cell activity and subsets.
METHOD OF STUDY:
MIVIg treatment was performed in 18 pregnancies from 15 women with 4 or more consecutive RSA of unexplained etiology. NK cell activity and subsets were assessed in 8 of the pregnancies.
RESULTS:
14 pregnancies resulted in live births and 4 resulted in abortions with chromosome abnormality. The pre-infusion NK cell activity (mean + SD. 40.9 + 17.0%) at 4.4 +/- 0.5 weeks of gestation (GW) decreased to 15.0 +/- 7.90% at post-infusion status (5.4 +/- 0.5 GW). Pre-infusion percentages of CD56+ CD16- cells (3.5 +/- 2.1%) and CD56+ CD16- cells (16.8 +/- 8.8%) decreased to 3.0 +/- 2.2% and 11.1 +/- 6.9%, respectively, after MIVIg treatment.
CONCLUSIONS:
MIVIg treatment was effective in all 14 pregnancies from RSA women of unexplained etiology, excluding 4 abortions with chromosome abnormality. Peripheral NK cell activity and subsets were suppressed by MIVIg treatment.
AuthorsM Morikawa, H Yamada, E H Kato, S Shimada, T Kishi, T Yamada, G Kobashi, S Fujimoto
JournalAmerican journal of reproductive immunology (New York, N.Y. : 1989) (Am J Reprod Immunol) Vol. 46 Issue 6 Pg. 399-404 (Dec 2001) ISSN: 1046-7408 [Print] Denmark
PMID11775009 (Publication Type: Journal Article)
Chemical References
  • Biomarkers
  • CD56 Antigen
  • Immunoglobulins, Intravenous
  • Receptors, IgG
Topics
  • Abortion, Habitual (drug therapy, etiology, immunology)
  • Abortion, Spontaneous (drug therapy, etiology, immunology)
  • Adult
  • Biomarkers
  • CD56 Antigen
  • Down-Regulation (immunology)
  • Female
  • Humans
  • Immunoglobulins, Intravenous (therapeutic use)
  • Killer Cells, Natural (immunology)
  • Pregnancy
  • Pregnancy Outcome
  • Receptors, IgG

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: